Asacol®-induced neutropenia resolution without the use of granulocyte colony-stimulating factor

Southern Medical Journal

Volumn 103, Issue 11, 2010, Pages 1167-1169

  Fowler, Brian T ^a   Gupta, Tina ^a   Bilal, Muhammad ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Asacol; filgrastrim; inflammatory bowel disease; mesalamine; neutropenia

Indexed keywords

AMIODARONE; AMPHOTERICIN B; ANTIBIOTIC AGENT; INSULIN GLARGINE; ITRACONAZOLE; LEVOTHYROXINE; MESALAZINE; METFORMIN; METHOTREXATE; OMEPRAZOLE; PROPAFENONE; RANITIDINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ROSIGLITAZONE; WARFARIN;

ABDOMINAL PAIN; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; BLOOD CULTURE; BONE MARROW BIOPSY; CASE REPORT; CAUCASIAN; CHRONIC DISEASE; COLONIC HISTOPLASMOSIS; COMPUTER ASSISTED TOMOGRAPHY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FLOW CYTOMETRY; GRAM NEGATIVE SEPSIS; HEART ATRIUM FIBRILLATION; HISTOPLASMOSIS; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; KERATODERMA; LEUKOCYTE COUNT; MALE; NEUTROPHIL COUNT; PSEUDOMONAS AERUGINOSA; ULCERATIVE COLITIS;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; MESALAMINE; NEUTROPENIA;

EID: 78549281710     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e3181f46647     Document Type: Article

References (11)

1. Sweetman S. Martindale: The Complete Drug Reference (electronic version). London, Pharmaceutical Press, ed 34, 2004.
2. Loftus EV Jr, Kane SV, Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ul-cerative colitis [review]. Aliment Pharmacol Ther 2004;19:179-189.
3. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 2002;51:536-9.
4. Cunliffe RN, Scott BB. Review article: monitoring for drug side-effects in inflammatory bowel disease. Aliment Pharmacol Ther 2002;16:647-662.
5. Jick H, Wald Myers M, Dean AD. The risk of sulfasalazine-and mesala-zine-associated blood disorders. Pharmacotherapy 1995;15:176-181.
6. Wyatt S, Joyner MV, Daneshmend TK. Filgrastim for mesalazine-asso-ciated neutropenia. Lancet 1993;341:1476.
7. Bhidayasiri R, Katz JA, Sokos DR. Correction of mesalazine-induced neutropenia with high-dose G-CSF. Am J Gastroenterol 2000;95:3321-3322.
8. Delgado-Riley AM, Roger V, Zabeleta IA, et al. Mesalamine associated neutropenia in a newborn. Int Pediatr 2002;17:54-56.
9. Kotanagi H, Ito M, Koyama K, et al. Pancytopenia associated with 5-aminosalicylic acid use in a patient with Crohn's disease. J Gastro-enterol 1998;33:571-574.
10. Turunen U, Elomaa I, Anttila VJ, et al. Mesalazine tolerance in patients with inflammatory bowel disease and previous intolerance or allergy to sulphasalazine or sulphonamides. Scan J Gastroenterol 1987;22:798-802.
11. Marteau P, Nelet F, Le Lu M, et al. Adverse events in patients treated with 5-aminosalicyclic acid: 1993-1994 pharmacovigilance report for Pentasa in France. Aliment Pharmacol Ther 1996;10:949-956